PROBI AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 204 SEK | -1.92% |
|
-4.67% | +0.49% |
| 05-07 | Probi AB Approves Election of Stephanie Blum Sperisen as Board Member | CI |
| 05-07 | Probi AB Approves the Dividend for the Financial Year 2023 | CI |
| Sales 2024 * | 654M 61.36M 4.82B | Sales 2025 * | 699M 65.58M 5.16B | Capitalization | 2.37B 222M 17.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 15M 1.41M 111M | Net income 2025 * | 32M 3M 236M | EV / Sales 2024 * | 3.16 x |
| Net cash position 2024 * | 303M 28.43M 2.23B | Net cash position 2025 * | 345M 32.37M 2.54B | EV / Sales 2025 * | 2.9 x |
| P/E ratio 2024 * |
155
x | P/E ratio 2025 * |
74.6
x | Employees | - |
| Yield 2024 * |
0.72% | Yield 2025 * |
0.93% | Free-Float | 28.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Probi AB
More news
| 1 day | -1.92% | ||
| 1 week | -4.67% | ||
| Current month | +0.49% | ||
| 6 months | +0.49% | ||
| Current year | +0.49% |
1 week
204.00
214.00
1 month
199.00219.00
Current year
181.00239.00
1 year
171.50239.00
3 years
165.00660.00
5 years
139.20660.00
10 years
42.00660.00
| Managers | Title | Age | Since |
|---|---|---|---|
Anita Johansen
CEO | Chief Executive Officer | 52 | 31/03/22 |
| Director of Finance/CFO | 58 | 10-31 | |
Jörn Andreas
BRD | Director/Board Member | 44 | 31/12/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 12/05/20 | |
| Chairman | 60 | 31/03/15 | |
| Director/Board Member | 62 | 03/05/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/05/24 | 204 | -1.92% | 40 |
| 20/05/24 | 208 | +1.46% | 976 |
| 17/05/24 | 205 | -1.44% | 66 |
| 16/05/24 | 208 | -0.95% | 387 |
| 15/05/24 | 210 | -1.87% | 26 |
Delayed Quote Nasdaq Stockholm, May 21, 2024 at 08:44 am
More quotes
Probi AB is a Sweden-based company engaged in the probiotics research and development. The Companyâs activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The Company's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The Company is a parent of Probi Food AB and Probi Feed AB.
Sector
Pharmaceuticals
Calendar
16/07/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.49% | 222M | |
| +34.35% | 705B | |
| +30.71% | 583B | |
| -3.49% | 364B | |
| +20.15% | 332B | |
| +6.19% | 291B | |
| +15.80% | 238B | |
| -3.44% | 210B | |
| +10.43% | 209B | |
| +9.21% | 169B |
- Stock Market
- Equities
- PROB Stock
